%0 Journal Article
%T Chimeric antigen receptor T
%A Anna Dushenkov
%A Paiboon Jungsuwadee
%J Journal of Oncology Pharmacy Practice
%@ 1477-092X
%D 2019
%R 10.1177/1078155219836480
%X The Food and Drug Administration has recently approved two autologous chimeric antigen receptor T-cell immunotherapies tisagenlecleucel (Kymriah£¿) and axicabtagene ciloleucel (Yescarta£¿) for patients with advanced lymphocytic malignancies. Both immunotherapies target the CD19-positive B-cell neoplasms. Kymriah£¿ is indicated for the treatment of relapsed or refractory acute lymphoblastic leukemia and large B-cell lymphoma. Yescarta£¿ is indicated for lymphoma only. Although the new therapy offers a promise for patients with advanced disease, it is associated with adverse events including neurotoxicity and cytokine release syndrome, which can be fatal and may require a high level of multidisciplinary supportive care. Due to the risks, both Kymriah£¿ and Yescarta£¿ are subject to Risk Evaluation and Mitigation Strategy (REMS) protocols. As active members of multidisciplinary clinical teams, pharmacists are likely to be responsible for the execution of Kymriah£¿ and Yescarta£¿ REMS programs. This manuscript describes foundational science and clinical knowledge of chimeric antigen receptor T-cell immunotherapies, common therapy-specific toxicities and REMS requirements for Kymriah£¿ and Yescarta£¿ in relation to practice of pharmacy
%K Tisagenlecleucel
%K axicabtagene ciloleucel
%K tocilizumab
%K cytokine release syndrome
%K chimeric antigen receptor T-cell therapy
%K risk evaluation and mitigation strategy
%U https://journals.sagepub.com/doi/full/10.1177/1078155219836480